| Literature DB >> 28606101 |
Maja Di Rocco1, Genevieve Baujat2, Marta Bertamino3, Matthew Brown4, Carmen L De Cunto5, Patricia L R Delai6, Elisabeth M W Eekhoff7, Nobuhiko Haga8, Edward Hsiao9, Richard Keen10, Rolf Morhart11, Robert J Pignolo12, Frederick S Kaplan13.
Abstract
Fibrodysplasia ossificans progressiva (FOP), a disabling disorder of progressive heterotopic ossification (HEO), is caused by heterozygous gain-of- function mutations in Activin receptor A, type I (ACVR1, also known as ALK2), a bone morphogenetic protein (BMP) type I receptor. Presently, symptomatic management is possible, but no definitive treatments are available. Although extensive guidelines for symptomatic management are widely used, regional preferences exist. In order to understand if there was worldwide consensus among clinicians treating FOP patients, an expert panel of physicians directly involved in FOP patient care was convened. Using a modified Delphi method, broad international consensus was reached on four main topics: diagnosis, prevention of flare-ups, patient and family-centered care and general clinical management issues. This study of physician preferences provides a basis for standardization of clinical management for FOP.Entities:
Keywords: ACVR1; Fibrodysplasia ossificans progressiva
Mesh:
Substances:
Year: 2017 PMID: 28606101 PMCID: PMC5468985 DOI: 10.1186/s13023-017-0659-4
Source DB: PubMed Journal: Orphanet J Rare Dis ISSN: 1750-1172 Impact factor: 4.123
Consensus statements
|
|
| Definitive diagnosis of FOP requires genetic confirmation |
|
|
| The prevention of flare-ups involves recognizing known causes of flare-up (blunt muscle trauma, muscle fatigue, muscular stretching, intramuscular injections) |
|
|
| Each patient should have a primary physician; not necessarily an FOP expert |
|
|
| FOP patients should be screened in childhood by audiometry for hearing impairment |